Heatwurx Inc.
PCSA- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
Follow PCSA
Alert me
Heatwurx Inc. (PCSA) EV/Sales
As of 19 November 2026, Heatwurx Inc. (PCSA) trades at a EV/Sales of −1,326×. Over the past ten years it has ranged from −1,334× (October 2026) to 2,590× (March 2015); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.1× and below the Healthcare sector median of 3.3×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 41.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2016 | 26.2× | (36.37%) |
| Dec 2015 | 41.2× | 3.62% |
| Sep 2015 | 39.8× | (48.03%) |
| Mar 2015 | 76.6× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCSA Heatwurx Inc. | −1,326× |
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| JAGX Jaguar Animal Health, Inc. compare | −0.1× |
| LTRN Lantern Pharma Inc. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.9× |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 18.0× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.4× |
| Biotechnology industry median | 9.1× |
| Healthcare sector median | 3.3× |
| Market median | 2.0× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)